The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.
Journal article
Kulkarni PS. et al, (2024), Lancet
Immune responses to typhoid conjugate vaccine in a two dose schedule among Nepalese children <2 years of age.
Journal article
Bijukchhe SM. et al, (2024), Vaccine
Molecular correlates of vaccine-induced protection against typhoid fever.
Journal article
Zhu H. et al, (2023), J Clin Invest, 133
Distinct glycosylation and functional profile of typhoid vaccine-induced antibodies in a UK challenge study and Nepalese children.
Journal article
HILL J. et al, (2022), Frontiers in Analytical Science
Genetic Susceptibility to Enteric Fever in Experimentally Challenged Human Volunteers.
Journal article
Barton A. et al, (2022), Infect Immun, 90
Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial.
Journal article
Shakya M. et al, (2021), Lancet Glob Health, 9, e1561 - e1568
Persistence of Antibody After a Vi-Tetanus Toxoid Conjugate Vaccine and Effect of Boosting With a Plain Polysaccharide Vaccine on Vi Antibody and Antigen-Specific B Cells
Journal article
Bentley T. et al, (2021), Frontiers in Tropical Diseases, 2
Association of Antibody-Dependent Neutrophil Phagocytosis With Distinct Antibody Glycosylation Profiles Following Typhoid Vaccination
Journal article
Johnson M. et al, (2021), Frontiers in Tropical Diseases, 2
A Salmonella Typhi Controlled Human Infection Study for Assessing Correlation between Bactericidal Antibodies and Protection against Infection Induced by Typhoid Vaccination.
Journal article
Jones E. et al, (2021), Microorganisms, 9
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Journal article
Voysey M. et al, (2021), Lancet, 397, 881 - 891
Vi-specific serological correlates of protection for typhoid fever.
Journal article
Jin C. et al, (2021), J Exp Med, 218
ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 - Authors' reply.
Journal article
Voysey M. and Pollard AJ., (2020), Lancet, 396, 1486 - 1487
Homologous and heterologous re-challenge with Salmonella Typhi and Salmonella Paratyphi A in a randomised controlled human infection model.
Journal article
Gibani MM. et al, (2020), PLoS Negl Trop Dis, 14
Evaluation of a standardised Vi poly-l-lysine ELISA for serology of Vi capsular polysaccharide antibodies.
Journal article
Rigsby P. et al, (2020), Biologicals, 66, 21 - 29
Vi-Vaccinations Induce Heterogeneous Plasma Cell Responses That Associate With Protection From Typhoid Fever.
Journal article
Cross DL. et al, (2020), Front Immunol, 11
Investigation of the role of typhoid toxin in acute typhoid fever in a human challenge model.
Journal article
Gibani MM. et al, (2019), Nat Med, 25, 1082 - 1088
The Impact of Vaccination and Prior Exposure on Stool Shedding of Salmonella Typhi and Salmonella Paratyphi in 6 Controlled Human Infection Studies.
Journal article
Gibani MM. et al, (2019), Clin Infect Dis, 68, 1265 - 1273
IgA and IgG1 Specific to Vi Polysaccharide of Salmonella Typhi Correlate With Protection Status in a Typhoid Fever Controlled Human Infection Model.
Journal article
Dahora LC. et al, (2019), Front Immunol, 10
Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.
Journal article
Jin C. et al, (2017), Lancet, 390, 2472 - 2480
Salmonella Typhi Bactericidal Antibodies Reduce Disease Severity but Do Not Protect against Typhoid Fever in a Controlled Human Infection Model.
Journal article
Juel HB. et al, (2017), Front Immunol, 8